What is Zacks Research’s Forecast for Revvity Q2 Earnings?

Revvity Inc. (NYSE:RVTY) – Equities researchers at Zacks Research lowered their Q2 2028 earnings per share (EPS) estimates for Revvity in a research report issued on Thursday, June 25th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.64 for the quarter, down from their prior forecast of $1.66. The consensus estimate for Revvity’s current full-year earnings is $5.25 per share.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $711.12 million for the quarter, compared to analysts’ expectations of $704.07 million. Revvity had a return on equity of 8.00% and a net margin of 8.26%.The business’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.01 EPS. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS.

RVTY has been the subject of a number of other research reports. JPMorgan Chase & Co. cut their price target on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. TD Cowen boosted their price objective on shares of Revvity from $115.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Sanford C. Bernstein initiated coverage on shares of Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price on the stock. Robert W. Baird set a $117.00 target price on shares of Revvity in a research note on Wednesday, May 6th. Finally, The Goldman Sachs Group reduced their price target on Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a report on Tuesday, April 14th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $108.33.

Revvity Price Performance

Shares of RVTY opened at $112.80 on Thursday. The company has a market cap of $12.58 billion, a price-to-earnings ratio of 53.97, a PEG ratio of 2.43 and a beta of 1.09. Revvity has a 1-year low of $81.22 and a 1-year high of $118.30. The company’s fifty day simple moving average is $98.62 and its 200 day simple moving average is $97.94. The company has a current ratio of 1.72, a quick ratio of 1.41 and a debt-to-equity ratio of 0.37.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 7th. Shareholders of record on Friday, July 17th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date of this dividend is Friday, July 17th. Revvity’s payout ratio is 13.40%.

Hedge Funds Weigh In On Revvity

Large investors have recently modified their holdings of the stock. Ascentis Independent Advisors acquired a new stake in shares of Revvity during the 1st quarter worth about $29,000. CYBER HORNET ETFs LLC acquired a new position in Revvity in the 2nd quarter valued at about $32,000. Cromwell Holdings LLC grew its stake in Revvity by 141.4% in the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock valued at $33,000 after buying an additional 198 shares during the last quarter. MUFG Securities EMEA plc bought a new position in Revvity in the 2nd quarter valued at about $34,000. Finally, SJS Investment Consulting Inc. raised its holdings in Revvity by 5,210.0% in the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock valued at $47,000 after acquiring an additional 521 shares during the period. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.